Standard BioTools Inc
LAB1.305USD
+0.005+0.38%
Market hours （ET）Quotes delayed by 15 min
494.71MMarket Cap
LossP/E TTM
More Details of Standard BioTools Inc Company
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Company Info
Ticker SymbolLAB
Company nameStandard BioTools Inc
IPO dateFeb 10, 2011
CEODr. Michael Egholm, Ph.D.
Number of employees818
Security typeOrdinary Share
Fiscal year-endFeb 10
Address2 Tower Place
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16502666000
Websitehttps://www.standardbio.com/
Ticker SymbolLAB
IPO dateFeb 10, 2011
CEODr. Michael Egholm, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+151.54%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
105.09K
-37.30%
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Troy Cox
Mr. Troy Cox
Independent Director
Independent Director
--
--
Ms. Kathy Hibbs
Ms. Kathy Hibbs
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Hanjoon Alex Kim
Mr. Hanjoon Alex Kim
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Franklin R. (Frank) Witney, Ph.D.
Dr. Franklin R. (Frank) Witney, Ph.D.
Independent Director
Independent Director
--
--
Mr. Thomas (Tom) Carey
Mr. Thomas (Tom) Carey
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+151.54%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
105.09K
-37.30%
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Troy Cox
Mr. Troy Cox
Independent Director
Independent Director
--
--
Ms. Kathy Hibbs
Ms. Kathy Hibbs
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Services
17.61M
43.16%
Consumables
14.45M
35.43%
Instruments
7.78M
19.07%
Other revenue
956.00K
2.34%
By RegionUSD
Name
Revenue
Proportion
Americas
18.97M
46.51%
Europe & Middle East & Africa (EMEA)
12.61M
30.90%
Asia-Pacific
9.21M
22.59%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Services
17.61M
43.16%
Consumables
14.45M
35.43%
Instruments
7.78M
19.07%
Other revenue
956.00K
2.34%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Casdin Capital, LLC
20.03%
Viking Global Investors LP
15.44%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
4.52%
Morgan Stanley Investment Management Inc. (US)
2.60%
Other
51.53%
Shareholders
Shareholders
Proportion
Casdin Capital, LLC
20.03%
Viking Global Investors LP
15.44%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
4.52%
Morgan Stanley Investment Management Inc. (US)
2.60%
Other
51.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
29.08%
Hedge Fund
27.61%
Investment Advisor
14.98%
Individual Investor
1.52%
Venture Capital
0.62%
Research Firm
0.52%
Bank and Trust
0.22%
Pension Fund
0.12%
Private Equity
0.03%
Other
25.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
332
283.42M
74.62%
-28.16M
2025Q1
336
286.88M
75.60%
-24.96M
2024Q4
322
279.84M
75.18%
-22.14M
2024Q3
315
282.67M
78.53%
-14.93M
2024Q2
303
268.49M
74.97%
-14.97M
2024Q1
306
263.03M
71.99%
+131.65M
2023Q4
264
54.09M
66.99%
-14.10M
2023Q3
265
53.37M
67.31%
-13.39M
2023Q2
273
51.56M
65.50%
-19.05M
2023Q1
294
52.71M
66.75%
-21.93M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Casdin Capital, LLC
76.08M
20.03%
--
--
Apr 15, 2025
Viking Global Investors LP
58.65M
15.44%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.35M
5.88%
-330.50K
-1.46%
Mar 31, 2025
The Vanguard Group, Inc.
17.17M
4.52%
+69.10K
+0.40%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
9.86M
2.6%
-5.85M
-37.23%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.21M
1.9%
+230.24K
+3.30%
Mar 31, 2025
Long Focus Capital Management LLC
6.70M
1.76%
+6.70M
--
Mar 31, 2025
Tikvah Management LLC
6.55M
1.72%
--
--
Mar 31, 2025
State Street Global Advisors (US)
6.36M
1.67%
+69.13K
+1.10%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
6.23M
1.64%
-384.70K
-5.81%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.54%
ARK Genomic Revolution ETF
0.36%
iShares Micro-Cap ETF
0.08%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.03%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.54%
ARK Genomic Revolution ETF
Proportion0.36%
iShares Micro-Cap ETF
Proportion0.08%
iShares Biotechnology ETF
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
